FDA approves Novartis' Lutathera for GEP-NETs
FDA approved Lutathera (177-Lu-Dotatate) from Novartis AG (NYSE:NVS; SIX:NOVN) to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults, including foregut, midgut, and hindgut neuroendocrine tumors. Novartis gained the drug when it acquired Advanced Accelerator Applications S.A. for $3.9 billion in a deal that closed this week (see BioCentury Extra, Oct. 30, 2017).
FDA said Lutathera, which is a radiolabeled somatostatin analog that targets somatostatin receptors, is the first radioactive drug approved in the indication. The European Commission approved Lutathera in September 2017 (see BioCentury Extra, Sept. 29, 2017)...
BCIQ Target Profiles